A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative (64)Cu-Labeled Chelator in Mouse Models.
A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative (64)Cu-Labeled Chelator in Mouse Models.
复制标题
基于PET放射组学的新临床前决策支持系统：在小鼠模型中评价创新的（64）Cu标记螯合剂的初步研究。
DOI：
10.3390/jimaging8040092
复制
发表时间：
2022-03-30
影响因子：
3.2
通讯作者：
中科院分区：
文献类型：
--
作者：
通过正电子发射断层扫描（PET）成像在体内分析64 Cu标记的螯合剂，以评估其在不同采集时间在小鼠模型中的生物分布。为此，9只6周龄雌性Balb/C裸小鼠在注射64 Cu标记的螯合剂后的三个不同时间点进行微PET成像。具体地，将小鼠分成组1（在[64 Cu]螯合剂施用后1小时采集，n = 3只小鼠）、组2（在[64 Cu]螯合剂施用后4小时采集，n = 3只小鼠）和组3（在[64 Cu]螯合剂施用后24小时采集，n = 3只小鼠）。随后，所有PET研究通过与标准模板空间（3D全身Digimouse图谱）配准进行分割，并从7个器官（即心脏、膀胱、胃、肝、脾、肾和肺）中提取108个放射组学特征，以研究[64 Cu]螯合剂生物分布随时间的可能变化。单因素方差分析和事后Tukey Honestly显著性差异检验显示，心、胃、脾、肾和肺区域的放射组学特征的百分比非常低，具有显著性差异（p值< 0.05）在三组小鼠中，存在大量特征在膀胱和肝脏中观察到组间显著变化的64 Cu标记的螯合剂的吸收率（分别大于60%和50%），表明64 Cu标记的螯合剂随时间的体内吸收不同。所提出的方法可以改进计算[64 Cu]螯合剂生物分布的方法，并为临床前成像试验中使用的新放射性药物领域的决策支持系统开辟道路。
The 64Cu-labeled chelator was analyzed in vivo by positron emission tomography (PET) imaging to evaluate its biodistribution in a murine model at different acquisition times. For this purpose, nine 6-week-old female Balb/C nude strain mice underwent micro-PET imaging at three different time points after 64Cu-labeled chelator injection. Specifically, the mice were divided into group 1 (acquisition 1 h after [64Cu] chelator administration, n = 3 mice), group 2 (acquisition 4 h after [64Cu]chelator administration, n = 3 mice), and group 3 (acquisition 24 h after [64Cu] chelator administration, n = 3 mice). Successively, all PET studies were segmented by means of registration with a standard template space (3D whole-body Digimouse atlas), and 108 radiomics features were extracted from seven organs (namely, heart, bladder, stomach, liver, spleen, kidney, and lung) to investigate possible changes over time in [64Cu]chelator biodistribution. The one-way analysis of variance and post hoc Tukey Honestly Significant Difference test revealed that, while heart, stomach, spleen, kidney, and lung districts showed a very low percentage of radiomics features with significant variations (p-value < 0.05) among the three groups of mice, a large number of features (greater than 60% and 50%, respectively) that varied significantly between groups were observed in bladder and liver, indicating a different in vivo uptake of the 64Cu-labeled chelator over time. The proposed methodology may improve the method of calculating the [64Cu]chelator biodistribution and open the way towards a decision support system in the field of new radiopharmaceuticals used in preclinical imaging trials.